Document Detail

Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy.
MedLine Citation:
PMID:  7552693     Owner:  NLM     Status:  MEDLINE    
The correction of genetically based disorders by the introduction of a therapeutic genetic construct into the appropriate cell type ("gene therapy"), has become a distinct possibility in recent years. In order for gene therapy to be a practical alternative to more conventional pharmaceutical approaches to treatment, it must be administrable in vivo. This demands that a system be developed that can specifically target the DNA to the desired cell type once introduced into the patient. Among the procedures that are currently being pursued, the delivery of DNA to cells by receptor mediated endocytosis (RME), comes closest to fulfilling this crucial requirement. The natural physiological process of RME can be exploited to deliver genetic material to cells. An antibody or ligand to a cell surface receptor that is known to undergo endocytosis, is complexed with DNA through a covalently linked polycationic adjunct (e.g., polylysine, protamines). Such complexes retain their binding specificity to the cell surface and are taken up into the cell where they enter the endosomal compartment via normal endocytotic processes. In addition, steps must be taken to avoid degradation of the DNA within the endosome-lysosome. Cells can be treated with the lysosomatropic agent chloroquine during the transfection procedure. Alternatively, the components of viruses that enter cells by endocysis and possess an endosomal "break out" capacity can be used. Replication defective adenovirus coupled to the ligand-DNA complex gives transfection efficiencies of virtually 100% on tissue culture cells in vitro. Synthetic peptides that mimic the membrane fusing region of influenza virus hemagglutinin, have also been successfully used as part of the ligand-DNA complex to bring about endosomal escape. Preliminary studies have demonstrated the potential of this method to specifically target DNA to the cell type of choice in vivo. Delivery of genes by receptor-mediated endocytosis offers the greatest hope that gene therapy can be an inexpensive, easily applicable, widespread technology.
J Guy; D Drabek; M Antoniou
Related Documents :
2159263 - Studies on saccharomyces cerevisiae under carbon-limiting growth transformed with plasm...
8919823 - A titration procedure of the junonia coenia densovirus and quantitation of transfection...
193993 - Antibody-dependent, eosinophil-mediated damage to 51cr-labeled schistosomula of schisto...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Molecular biotechnology     Volume:  3     ISSN:  1073-6085     ISO Abbreviation:  Mol. Biotechnol.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-11-06     Completed Date:  1995-11-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423533     Medline TA:  Mol Biotechnol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  237-48     Citation Subset:  IM    
Laboratory of Gene Structure and Expression, National Institute for Medical Research, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA / genetics*,  physiology
Drug Delivery Systems
Gene Therapy*
Gene Transfer Techniques*
Receptors, Cell Surface / physiology*
Reg. No./Substance:
0/Receptors, Cell Surface; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The potential exploitation of plant viral translational enhancers in biotechnology for increased gen...
Next Document:  Multiple peptide synthesis.